Merger Notification - Announcement according to § 10 Cartel Act
Pfizer, Inc.; exklusive und co-exklusive Lizenzrechte für den Vertrieb, die Entwicklung und die Herstellung bestimmter Wirkstoffe von Biohaven Pharmaceutical Holding Company Ltd. in New Haven, USA zur Behandlung von Migräne
BWB/Z-5782
On 26.11.2021 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Notified with the FCA on November 26, 2021, was the following transaction: Pfizer Inc (“Pfizer”) seeks to acquire via its subsidiary Pfizer Ireland Pharmaceuticals ("Pfizer Ireland"), Ringaskiddy, Ireland, exclusive and co-exclusive licensing rights for the distribution, development, and manufacturing of certain compounds from Biohaven Pharmaceutical Holding Company Ltd., New Haven, USA (“Biohaven”) for the treatment of migraine.
Type of business: discovery, development, and commercialization of compounds and products to treat migraine.
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 27.12.2021.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 28.12.2021 .